Skip to main content
Erschienen in: Endocrine 3/2012

01.12.2012 | Original Article

Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells

verfasst von: Zhipeng Su, Xiaolong Jiang, Chengde Wang, Jie Liu, Yunxiang Chen, Qun Li, Jinsen Wu, Weiming Zheng, Qichuan Zhuge, Kunlin Jin, Zhebao Wu

Erschienen in: Endocrine | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Nerve growth factor (NGF) can increase expression of dopamine 2 receptors (D2R) in GH3 rat pituitary tumor cells (GH3 cells). As D2R exists in long (D2L) and short (D2S) isoforms, effects of NGF on D2R subtypes have not been accurately evaluated. In this study, we compared mRNA levels of D2R subtypes in GH3 cells treated with or without NGF with real-time RT-PCR. In addition, we also evaluated the relationship between GH3 cell growth after bromocriptine treatment and mRNA levels of D2R subtypes. We found that D2R total, D2L, and D2S mRNA in GH3 cells were significantly increased after NGF treatment, compared with the vehicle group. Moreover, NGF increased the ratio of D2S to D2L. GH3 cell survival rate after bromocriptine treatment was negatively correlated with D2R total mRNA, and D2S may be more potent than D2L in inhibiting cell growth. Cell apoptosis rate was highly elevated in GH3 cells treated with NGF and bromocriptine, compared with the control group or the group treated with NGF or bromocriptine alone. Our data provide preliminary evidence that the effect of NGF was more prominent on expression of D2S than D2L, in addition, D2S might have a greater impact suppressing GH3 cells growth than D2L.
Literatur
1.
Zurück zum Zitat B. Giros, P. Sokoloff, M.P. Martres, J.F. Riou, L.J. Emorine, J.C. Schwartz, Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342, 923–926 (1989)PubMedCrossRef B. Giros, P. Sokoloff, M.P. Martres, J.F. Riou, L.J. Emorine, J.C. Schwartz, Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342, 923–926 (1989)PubMedCrossRef
2.
Zurück zum Zitat J.A. Gingrich, M.G. Caron, Recent advances in the molecular biology of dopamine receptors. Ann. Rev. Neurosci. 16, 299–321 (1993)PubMedCrossRef J.A. Gingrich, M.G. Caron, Recent advances in the molecular biology of dopamine receptors. Ann. Rev. Neurosci. 16, 299–321 (1993)PubMedCrossRef
3.
Zurück zum Zitat S.E. Wolfe, S.J. Morris, Dopamine D2 receptor isoforms expressed in AtT20 cells differentially couple to G proteins to acutely inhibit high voltage-activated calcium channels. J. Neurochem. 73, 2375–2382 (1999)PubMedCrossRef S.E. Wolfe, S.J. Morris, Dopamine D2 receptor isoforms expressed in AtT20 cells differentially couple to G proteins to acutely inhibit high voltage-activated calcium channels. J. Neurochem. 73, 2375–2382 (1999)PubMedCrossRef
4.
Zurück zum Zitat M.E. Molitch, Medical treatment of prolactin-secreting pituitary adenomas. Pituitary 5, 55–65 (2002)PubMedCrossRef M.E. Molitch, Medical treatment of prolactin-secreting pituitary adenomas. Pituitary 5, 55–65 (2002)PubMedCrossRef
5.
Zurück zum Zitat Z.B. Wu, C.J. Yu, Z.P. Su, Q.C. Zhuge, J.S. Wu, W.M. Zheng, Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J. Neurosurg. 104, 54–61 (2006)PubMedCrossRef Z.B. Wu, C.J. Yu, Z.P. Su, Q.C. Zhuge, J.S. Wu, W.M. Zheng, Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J. Neurosurg. 104, 54–61 (2006)PubMedCrossRef
6.
Zurück zum Zitat A. Colao, S. Savastno, Medical treatment of prolactinomas. Nat. Rev. Endocrinol. 7, 267–278 (2011)PubMedCrossRef A. Colao, S. Savastno, Medical treatment of prolactinomas. Nat. Rev. Endocrinol. 7, 267–278 (2011)PubMedCrossRef
7.
Zurück zum Zitat Y. Greenman, K. Tordjman, E. Osher, I. Veshchev, G. Shenkerman, I.I. Reider-Groswasser, Y. Segev, G. Ouaknine, N. Stern, Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin. Endocrinol. (Oxf) 63, 39–44 (2005)CrossRef Y. Greenman, K. Tordjman, E. Osher, I. Veshchev, G. Shenkerman, I.I. Reider-Groswasser, Y. Segev, G. Ouaknine, N. Stern, Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin. Endocrinol. (Oxf) 63, 39–44 (2005)CrossRef
8.
Zurück zum Zitat A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15, 905–915 (2008)PubMedCrossRef A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15, 905–915 (2008)PubMedCrossRef
9.
Zurück zum Zitat V.Q. Passos, M.A.H.Z. Fortes, D. Giannella-Neto, M.D. Bronstein, Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89, 163–170 (2009)PubMedCrossRef V.Q. Passos, M.A.H.Z. Fortes, D. Giannella-Neto, M.D. Bronstein, Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89, 163–170 (2009)PubMedCrossRef
10.
Zurück zum Zitat R. Pivonello, C. Matrone, M. Filippella, L.M. Cavallo, C. Di Somma, P. Cappabanca, A. Colao, L. Annunziato, G. Lombardi, Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J. Clin. Endocrinol. Metab. 89, 1674–1683 (2004)PubMedCrossRef R. Pivonello, C. Matrone, M. Filippella, L.M. Cavallo, C. Di Somma, P. Cappabanca, A. Colao, L. Annunziato, G. Lombardi, Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J. Clin. Endocrinol. Metab. 89, 1674–1683 (2004)PubMedCrossRef
11.
Zurück zum Zitat U. Renner, T. Arzberger, U. Pagotto, S. Leimgruber, E. Uhl, A. Muller, M. Lange, A. Weindl, G.K. Stalla, Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 83, 1368–1375 (1998)PubMedCrossRef U. Renner, T. Arzberger, U. Pagotto, S. Leimgruber, E. Uhl, A. Muller, M. Lange, A. Weindl, G.K. Stalla, Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 83, 1368–1375 (1998)PubMedCrossRef
12.
Zurück zum Zitat C. Missale, F. Boroni, S. Sigala, A. Zanellato, R.D. Toso, A. Balsari, P.F. Spano, Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology 135, 290–298 (1994)PubMedCrossRef C. Missale, F. Boroni, S. Sigala, A. Zanellato, R.D. Toso, A. Balsari, P.F. Spano, Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology 135, 290–298 (1994)PubMedCrossRef
13.
Zurück zum Zitat C. Missale, M. Losa, S. Sigala, A. Balsari, M. Giovanelli, P.F. Spano, Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol. Endocrinol. 10, 272–285 (1996)PubMedCrossRef C. Missale, M. Losa, S. Sigala, A. Balsari, M. Giovanelli, P.F. Spano, Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol. Endocrinol. 10, 272–285 (1996)PubMedCrossRef
14.
Zurück zum Zitat C. Fiorentini, N. Guerra, M. Facchetti, A. Finardi, L. Tiberio, L. Schiaffonati, P.F. Spano, C. Missale, Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75NGFR-mediated activation of nuclear factor-κB. Mol. Endocrinol. 16, 353–366 (2002)PubMedCrossRef C. Fiorentini, N. Guerra, M. Facchetti, A. Finardi, L. Tiberio, L. Schiaffonati, P.F. Spano, C. Missale, Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75NGFR-mediated activation of nuclear factor-κB. Mol. Endocrinol. 16, 353–366 (2002)PubMedCrossRef
15.
Zurück zum Zitat L.V. Neto, E. de, O. Machado, R.M. Luque, G.F. Taboada, J.B. Marcondes, L.M. Chimelli, L.P. Quintella, P. Niemeyer Jr., D.P. de Carvalho, R.D. Kineman, M.R. Gadelha, Expression analysis of dopamine receptor subtype in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J. Clin. Endocrinol. Metab. 94, 1931–1937 (2009)PubMedCrossRef L.V. Neto, E. de, O. Machado, R.M. Luque, G.F. Taboada, J.B. Marcondes, L.M. Chimelli, L.P. Quintella, P. Niemeyer Jr., D.P. de Carvalho, R.D. Kineman, M.R. Gadelha, Expression analysis of dopamine receptor subtype in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J. Clin. Endocrinol. Metab. 94, 1931–1937 (2009)PubMedCrossRef
16.
Zurück zum Zitat C. de Bruin, A.M. Pereira, R.A. Feelders, J.A. Romijn, F. Roelfsema, D.M. Sprij-Mooij, M.O. van Aken, A.J. van der Lelij, W.W. de Herder, S.W. Lamberts, L.J. Hofland, Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J. Clin. Endocrinol. Metab. 94, 1118–1124 (2009)PubMedCrossRef C. de Bruin, A.M. Pereira, R.A. Feelders, J.A. Romijn, F. Roelfsema, D.M. Sprij-Mooij, M.O. van Aken, A.J. van der Lelij, W.W. de Herder, S.W. Lamberts, L.J. Hofland, Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J. Clin. Endocrinol. Metab. 94, 1118–1124 (2009)PubMedCrossRef
17.
Zurück zum Zitat T. Sasabe, E. Futai, S. Ishiura, Polypyrimidine tract-binding protein 1 regulates the alternative splicing of dopamine receptor D2. J. Neurochem. 116, 76–81 (2011)PubMedCrossRef T. Sasabe, E. Futai, S. Ishiura, Polypyrimidine tract-binding protein 1 regulates the alternative splicing of dopamine receptor D2. J. Neurochem. 116, 76–81 (2011)PubMedCrossRef
18.
Zurück zum Zitat L. Caccavelli, F. Feron, I. Morange, E. Rouer, R. Benarous, D. Dewailly, P. Jaquer, C. Kordon, A. Enjalbert, Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60, 314–322 (1994)PubMedCrossRef L. Caccavelli, F. Feron, I. Morange, E. Rouer, R. Benarous, D. Dewailly, P. Jaquer, C. Kordon, A. Enjalbert, Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60, 314–322 (1994)PubMedCrossRef
19.
Zurück zum Zitat Z.B. Wu, W.M. Zheng, Z.P. Su, Y. Chen, J.S. Wu, C.D. Wang, C. Lin, Y.J. Zeng, Q.C. Zhuge, Expression of D2R mRNA isoforms and ER mRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J. Neurooncol. 99, 25–32 (2010)PubMedCrossRef Z.B. Wu, W.M. Zheng, Z.P. Su, Y. Chen, J.S. Wu, C.D. Wang, C. Lin, Y.J. Zeng, Q.C. Zhuge, Expression of D2R mRNA isoforms and ER mRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J. Neurooncol. 99, 25–32 (2010)PubMedCrossRef
20.
Zurück zum Zitat D.B. Radl, J. Ferraris, V. Boti, A. Seilicovich, D.K. Sarkar, D. Pisera, Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor. PLoS ONE 6, e18097 (2011)PubMedCrossRef D.B. Radl, J. Ferraris, V. Boti, A. Seilicovich, D.K. Sarkar, D. Pisera, Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor. PLoS ONE 6, e18097 (2011)PubMedCrossRef
Metadaten
Titel
Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells
verfasst von
Zhipeng Su
Xiaolong Jiang
Chengde Wang
Jie Liu
Yunxiang Chen
Qun Li
Jinsen Wu
Weiming Zheng
Qichuan Zhuge
Kunlin Jin
Zhebao Wu
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9715-y

Weitere Artikel der Ausgabe 3/2012

Endocrine 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.